Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
CONCLUSION: Results suggest that more than one-third of patients with RA with LDA or in remission may taper or stop DMARD treatment without experiencing a disease flare within the first year. Dose reduction of TNF blockers results in lower flare rates than stopping and may be noninferior to continuing full dose. Radiological progression after treatment deescalation remains low, but may increase slightly. PMID: 26428204 [PubMed - as supplied by publisher]
Conclusions: PET/CT images provide unique quantitative information that cannot be obtained from any other imaging modalities.
CONCLUSION: The RA-BIODAM prospective study succeeded in generating an extensive list of clinical, imaging (2343 radiographs), and biosample (4638 sera) resources that will be made available to expedite the identification and validation of biomarkers for radiographic damage endpoints. PMID: 31474600 [PubMed - as supplied by publisher]
CONCLUSION: FM0807 exerts its therapeutic effects on RA by inhibiting cartilage degeneration. FM0807 treatment might be an effective therapeutic approach for RA. PMID: 31431516 [PubMed - as supplied by publisher]
ConclusionAbnormalities were identified in 79% of chest radiographs in RA patients. Sixty-six percent of these were not reported. Clinicians need to be aware of the need to check for abnormalities.Key Points•RA patients have a high prevalence of CXR abnormalities.•Many of these are of clinical significance.•Age, being male, and seropositivity were associated with lung abnormalities.
AbstractBCD-055 is a biosimilar of innovator infliximab (IFX). Here we present the 54-week results from phase 3 clinical study in patients with rheumatoid arthritis (RA). The aim of this study was to demonstrate the equivalent efficacy and safety of BCD-055 and IFX in patients with active rheumatoid arthritis. 426 adults with active RA were enrolled. Patients were randomized into 2 study arms in 2:1 ratio to receive BCD-055 or IFX innovator in dose of 3 mg/kg at week 0, 2, 6 and then every 8 weeks up to week 54. Primary efficacy endpoint was the rate of American College of Rheumatology (ACR) 20 response at week ...
ConclusionThe cost per responder and patient in remission favoured abatacept in patients with seropositive, erosive early RA across all the countries. In this patient population, the use of abatacept instead of adalimumab can lead to lower costs in the US, Germany, Spain, and Canada.
Authors: Direito R, Rocha J, Serra AT, Fernandes A, Freitas M, Fernandes E, Pinto R, Bronze R, Sepodes B, Figueira ME Abstract Persimmon (Diospyros kaki L.) fruits are used in traditional medicine largely due to their claimed beneficial effects on human health. The aim of this work was to evaluate the anti-inflammatory activity of a persimmon extract in rats with collagen-induced arthritis (CIA). CIA was induced in Wistar rats through an intradermal injection of an emulsion of bovine type II collagen (CII) in complete Freund's adjuvant (FCA). Macroscopic evidence of CIA first appeared as periarticular erythema and ...
CONCLUSION: Eighteen percent of patients with RA had a history compatible with PR previous to RA onset. No specific clinical or serological phenotype was identified in these patients, although higher hydroxychloroquine use and smoking prevalence were identified. Palindromic flares may persist during the RA disease course despite treatment. PMID: 31371648 [PubMed - as supplied by publisher]
Conclusion: These results demonstrate that PE exerts an inhibitory role in FLSs and CIA rats, and therefore may have therapeutic value for the treatment of RA. PMID: 31354003 [PubMed - as supplied by publisher]
Conclusion: USG can detect inflammatory arthritis and synovitis in RA better than CR in both early and established cases. USG findings may be seen in clinically uninvolved joints. Detection of erosions is also significantly better by USG as compared to CR. USG changes correlated with anti CCP and CRP. PMID: 31331131 [PubMed - in process]